ArticleInternational ophthalmology2025
Clinical outcomes of femtosecond laser-assisted laser in situ keratomileusis combined with accelerated corneal cross-linking versus standard femtosecond laser-assisted laser in situ keratomileusis for the correction of myopia and myopic astigmatism.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the long-term clinical outcomes of femtosecond laser-assisted laser in situ keratomileusis combined with accelerated corneal cross-linking (FS-LASIK Xtra) in patients with refractive error, evaluating its safety, efficacy, and stability.
methodsThis retrospective comparative study included 80 eyes of 40 patients, divided into an FS-LASIK Xtra group (40 eyes) and a standard FS-LASIK group (40 eyes). Clinical outcomes, including visual acuity, refractive status, posterior corneal elevation, higher-order aberrations (HOAs), and corneal biomechanics, were evaluated preoperatively and up to 12 months postoperatively.
resultsAt 1 year, both groups achieved excellent uncorrected distance visual acuity (UDVA), although the median UDVA was statistically slightly better in the standard FS-LASIK group (P = 0.036). The spherical equivalent (SE) was comparable between the groups (P = 0.172). Regarding the posterior corneal surface, the standard FS-LASIK group demonstrated a significant progressive forward shift (P < 0.001), while the FS-LASIK Xtra group remained stable (P = 0.209). The change in the biomechanical integrated radius (ΔIR) was significantly smaller in the FS-LASIK Xtra group, indicating better biomechanical preservation (P = 0.032). While total higher-order aberrations increased in both groups, horizontal trefoil was significantly higher in the FS-LASIK Xtra group (P = 0.004).
conclusionFS-LASIK Xtra demonstrated advantages in maintaining posterior corneal surface stability and better preserving corneal biomechanical properties over a 1-year follow-up period. Combining FS-LASIK with accelerated corneal cross-linking may serve as an enhancement strategy, providing additional structural support following the procedure.
Indexed as
Identifiers
41247447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.